Meeting
2020 ASCO Virtual Scientific Program
SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).
Authors
Natasha B. Leighl
Princess Margaret Cancer Centre, Toronto, ON, Canada
Natasha B. Leighl , Mary Weber Redman , Naiyer A. Rizvi , Fred R. Hirsch , Philip C. Mack , Lawrence Howard Schwartz , James Lloyd Wade III, William Johnson Irvin Jr., Sreekanth Reddy , Jeffrey Crawford , Jeffrey D. Bradley , Tom Stinchcombe , Suresh S. Ramalingam , Jieling Miao , Katherine Minichiello , David R. Gandara , Roy S. Herbst , Vassiliki Papadimitrakopoulou , Karen Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03373760
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9623)
DOI
10.1200/JCO.2020.38.15_suppl.9623
Abstract #
9623
Poster Bd #
389
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.
First Author: William Joseph Chapin
Poster
2022 ASCO Annual Meeting
Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.
First Author: Edwin R. Parra
Poster
2022 ASCO Annual Meeting
Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC).
First Author: Thierry Andre
Poster
2021 ASCO Annual Meeting
NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094).
First Author: Jose Lutzky